Boehringer Ingelheim
This website is for UK Healthcare Professionals. If you are a patient or member of the public please visit our public website here
Find adverse event reporting information at the bottom of this page
Contact
Boeringer Ingelheim Logo
Boeringer Ingelheim
Boeringer Ingelheim Logo
Boeringer Ingelheim
Boeringer Ingelheim Logo
Boeringer Ingelheim
  • Diseases
    Diseases

    • Diseases
    • Chronic Heart Failure (CHF) Opens in new tab
    • Chronic Kidney Disease (CKD) Opens in new tab
    • Idiopathic Pulmonary Fibrosis (IPF)
    • Progressive Pulmonary Fibrosis (PPF)
    • Stroke
    • Type 2 Diabetes
  • Products
    Products

    • Products
    • Empagliflozin
    • JASCAYD®▼ (nerandomilast)

    • Linagliptin
    • METALYSE 25 mg (tenecteplase)
    • OFEV® (nintedanib)
  • Resources
    Resources

    • Resources
      • Healthcare Professional Resources
      • Acute Ischaemic Stroke
      • Cardio Renal Metabolism
  • Click here to join
    our mailing list to hear
    news & updates about our products
    Opens in new tab
  • Find adverse event reporting information at the bottom of this page
  • Contact
Boeringer Ingelheim
Jascayd
Jascayd
Prescribing Information Opens in new tab
Safety Information
Jascayd logo
Jascayd
Jascayd logo
Jascayd
Jascayd logo
Jascayd
  • About JASCAYD®
  • Clinical evidence
  • Safety
  • Dosing
  • Jascayd
  • Prescribing Information Opens in new tab
  • Safety Information
Jascayd

Safety information

safety information banner

Indication

  • JASCAYD® is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).
  • JASCAYD® is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF).

Safety summary

JASCAYD® demonstrated an acceptable safety and tolerability profile vs. placebo in patients with PPF and IPF.1-5

When receiving JASCAYD® 18 mg +/- background AF:

Diarrhoea
 
  • For patients with PPF or IPF, diarrhoea was the most common AE. When diarrhoea occurred, it was of mild to moderate severity in most cases and experienced within the first 3 months of treatment3,*

Discontinuation
 

Discontinuations due to diarrhoea:3

Patients with PPF

  • JASCAYD® + background nintedanib:
    4% (7/170)
  • JASCAYD® monotherapy:
    1% (2/220)

Patients with IPF

  • JASCAYD® + background nintedanib:
    13% (23/178)
  • JASCAYD® + background pirfenidone:
    0% (0/127)
  • JASCAYD® monotherapy:
    1% (1/87)
liver monitoring
 
  • No routine liver monitoring required3,†

* Most cases of diarrhoea were grade 1 or 2 in Common Terminology Criteria for Adverse Events. Grade 1: increase of <4 stools per day; Grade 2: increase of 4–6 stools per day.6,7

† JASCAYD® is not recommended in patients with severe hepatic impairment.3

Most frequent adverse events in FIBRONEERTM-ILD trial

List of adverse events that occurred in ≥10% of patients with JASCAYD® ± nintedanib at end-of-trial analysis.8

Adverse event
Placebo ± nintedanib, n = 392
% (n)
JASCAYD® 18 mg ± nintedanib, n = 391
% (n)

Diarrhoea

26 (102)

37 (145)

Cough

16 (61)

17 (65)

Upper respiratory tract infection

17 (66)

14 (53)

Weight decreased

8 (32)

14 (56)

COVID-19

16 (62)

13 (51)

Nasopharyngitis

13 (49)

13 (49)

Pneumonia

10 (41)

13 (51)

Nausea

7 (28)

12 (47)

Anxiety

11 (42)

12 (45)

Condition aggravated

18 (71)

11 (43)

Depression

13 (50)

11 (44)

Dyspnoea

11 (43)

10 (41)

Please refer to the JASCAYD® Summary of Product Characteristics for further information.3

Most frequent adverse events in FIBRONEERTM-IPF trial

List of adverse events that occurred in ≥10% of patients with JASCAYD® ± background AF at end-of-trial analysis.9

Adverse event
Placebo ± background AF, n = 393
% (n)
JASCAYD® 18 mg ± background AF, n = 392
% (n)

Diarrhoea

18 (72)

42 (166)

Cough

19 (74)

17 (68)

COVID-19

15 (57)

15 (57)

Upper respiratory tract infection

11 (44)

14 (56)

Weight decreased

10 (38)

12 (48)

Nasopharyngitis

13 (50)

11 (45)

Dyspnoea

16 (63)

11 (42)

Condition aggravated

13 (52)

11 (45)

Decreased appetite

7 (27)

10 (40)

Bronchitis

10 (39)

9 (35)

Please refer to the JASCAYD® Summary of Product Characteristics for further information.3

Important safety information3

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, hypromellose 2910, talc, mannitol, macrogol 8000, iron oxide red (E172), iron oxide black (E172).

Drug interactions

Effects of other drugs on JASCAYD®

  • Strong CYP3A inhibitors: Reduce the dosage of JASCAYD® to 9 mg twice daily (BID) when used concomitantly with strong CYP3A inhibitors.
  • Moderate or strong CYP3A inducers: The recommended dosage of JASCAYD® is 18 mg BID and must not be reduced to 9 mg BID when used concomitantly with strong or moderate CYP3A inducers.
  • Pirfenidone: Concomitant use of JASCAYD® with pirfenidone decreased JASCAYD® exposure by approximately 50%. Recommended dosage of JASCAYD® is 18 mg BID when used concomitantly with pirfenidone. Do not reduce the dosage to 9 mg BID.

Precautions

  • Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Use in specific populations

  • Renal impairment: Use of JASCAYD® is not recommended in patients with end stage renal disease (eGFR<15 mL/minute/1.73 m2).
  • No dose adjustment is necessary in patients with mild, moderate, or severe renal impairment (eGFR≥15 and <90 mL/minute/1.73 m2, based on CKD-EPI formula).
  • Hepatic impairment: Use of JASCAYD® is not recommended in patients with severe (Child-Pugh Class C) hepatic impairment.
  • No dose adjustment is necessary in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment.

Fertility, pregnancy and lactation

  • Contraception: Females of reproductive potential should be advised to avoid becoming pregnant and to use effective contraceptive methods during treatment with JASCAYD®.
  • Pregnancy: JASCAYD® is not recommended during pregnancy. Advise female patients to notify their healthcare provider if they become pregnant or suspect they may be pregnant during therapy with JASCAYD®. Advise pregnant women and females of reproductive potential of the potential risk of foetal loss.
  • Breast-feeding: A risk to the breast-fed infant cannot be excluded. Breast-feeding should be discontinued during treatment with JASCAYD®.
  • Fertility: There are no data on the impact of JASCAYD® in human fertility.

Adverse reactions

MedDRA System
Organ Class terminology
MedDRA term
according to MedDRA 27.1
Frequency category
according to EU SPC guideline‡

Gastrointestinal disorders

Diarrhoea

Very common

Nausea

Common

Metabolism and nutrition disorders

Decreased appetite

Common

Investigations

Weight decreased

Very common

Musculoskeletal and connective tissue disorders

Back pain

Common

‡ Frequency categories: very common (≥1/10), common (≥1/100 – <1/10).

Please refer to the JASCAYD® Summary of Product Characteristics for further information.3

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events. Adverse event reporting information can be found at the bottom of this page.

Connect with your local representative

Have questions about JASCAYD® or the clinical data? Your local representative can provide further information and support.

Contact us

Get updated

Stay up to date with our events, products and resources for IPF and PPF

Subscribe

Abbreviations

AE: adverse event; AF: antifibrotic; BID: twice daily; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CYP3A: cytochrome P450, family 3, subfamily A; eGFR: estimated glomerular filtration rate; EU: European Union; IPF: idiopathic pulmonary fibrosis; PPF: progressive pulmonary fibrosis; SPC: Summary of Product Characteristics.

  1. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392(22):2193-2202.

  2. Maher TM, Assassi S, Azuma A, et al; FIBRONEER-ILD Trial Investigators. Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med. 2025;392(22):2203–2214.

  3. JASCAYD® 18 mg film-coated tablets. Summary of Product Characteristics. Boehringer Ingelheim.

  4. Wijsenbeek MS, Assassi S, Azuma A, et al. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial. Eur Respir J. 2026;68(1):2501899.

  5. Oldham JM, Azuma A, Kreuter M, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026;212(5):972-980.

  6. Wijsenbeek MS, Assassi S, Azuma A, et al. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial. Eur Respir J. 2026;68(1):2501899 (Supplementary).

  7. Oldham JM, Azuma A, Kreuter M, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026;212(5):972-980 (Supplementary).

  8. Data on file. Boehringer Ingelheim International GmbH. FIBRONEER-ILD CTR - SAFETY. 2025.

  9. Data on file. Boehringer Ingelheim International GmbH. FIBRONEER-IPF CTR - SAFETY. 2025.

PC-GB-112669 | October 2026

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone), or by e-mail: pv_local_uk_ireland@boehringer-ingelheim.com.

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Sitemap
  • Terms of Use
  • Accessibility Statement

Boehringer Ingelheim Logo
Boehringer Ingelheim

This information is for UK Healthcare Professionals only. Products discussed herein may have different labelling in different countries. 
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Notice.

Copyright © 2021-2026 Boehringer Ingelheim, Inc. All rights reserved. PC-GB-110791 V5 November 2026.